A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma.
about
Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and LomustineTrial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.Patient-Specific Screening Using High-Grade Glioma Explants to Determine Potential Radiosensitization by a TGF-β Small Molecule Inhibitor.Blockade of transforming growth factor-β signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models.Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models.Vaccine-based immunotherapeutic approaches to gliomas and beyond.Stromal dynamic reciprocity in cancer: intricacies of fibroblastic-ECM interactions.Targeting TGF-β Signaling for Therapeutic Gain.The EMT spectrum and therapeutic opportunities.Negative control of the HGF/c-MET pathway by TGF-β: a new look at the regulation of stemness in glioblastoma.Contemporary management of high-grade gliomas.Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor.Next generation of immune checkpoint therapy in cancer: new developments and challenges.Cytokines, breast cancer stem cells (BCSCs) and chemoresistanceLY2157299 Monohydrate, a TGF-βR1 Inhibitor, Suppresses Tumor Growth and Ascites Development in Ovarian Cancer
P2860
Q28078539-1E987062-95EA-424B-8FE3-603E3F733C2EQ33755077-1F2FB65F-2F91-4D2A-9FC7-9E1308C6392DQ37079141-51D190D0-210C-4393-8CD2-29F832530E73Q37503365-72BEA312-1F0D-437A-8747-54A776CB0D05Q38400073-83B13F72-4212-4E09-9E91-68F1C99C5027Q38616707-A3B23156-4F10-4B70-BD97-147875E8B506Q38789860-D2AA8057-557B-4D18-8049-0A297098E2B4Q38841939-CBE76AFB-9D74-4177-A8E7-D8BEBF0D93F3Q39155151-47D07C98-2D87-45EB-8CBF-60D4F0FA1632Q39329818-D07B9781-822A-4713-858E-303A4B74137CQ47296083-7D6FFE9A-653F-4DEC-868C-F961BEDAA09EQ47781482-080BEB4D-C6DB-4A25-9DCF-8C2F436B8FC3Q50173304-D123B956-6CC7-425D-9B80-D9CACD19D7A7Q52653710-DAF4EA0F-A8E6-4A48-BE92-103352146F79Q57106445-764A1BDD-6B1D-4A0E-8F46-A35966EB89D2Q58796872-E93D5413-EA1C-46E2-96E7-02CC1A69CF60
P2860
A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
A Phase II randomized study of ...... s with recurrent glioblastoma.
@en
A Phase II randomized study of ...... s with recurrent glioblastoma.
@nl
type
label
A Phase II randomized study of ...... s with recurrent glioblastoma.
@en
A Phase II randomized study of ...... s with recurrent glioblastoma.
@nl
prefLabel
A Phase II randomized study of ...... s with recurrent glioblastoma.
@en
A Phase II randomized study of ...... s with recurrent glioblastoma.
@nl
P2093
P2860
P50
P356
P1433
P1476
A Phase II randomized study of ...... s with recurrent glioblastoma.
@en
P2093
Alba A Brandes
Ann Cleverly
Antoine F Carpentier
Claire Smith
Colin Miles
Durisala Desaiah
Helen R Wheeler
Ivelina Gueorguieva
Joachim P Steinbach
Jordi Rodon
P2860
P304
P356
10.1093/NEUONC/NOW009
P577
2016-02-21T00:00:00Z